These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38920144)

  • 41. Ascites in the Course of Plasma Cell Myeloma Complicated by AL Amyloidosis.
    Debski J; Usnarska-Zubkiewicz L; Kapelko-Słowik K; Pawluś A; Zaleska-Dorobisz U; Kuliczkowski K
    Turk J Haematol; 2018 Mar; 35(1):71-72. PubMed ID: 27531413
    [No Abstract]   [Full Text] [Related]  

  • 42. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive Review of AL amyloidosis: some practical recommendations.
    Al Hamed R; Bazarbachi AH; Bazarbachi A; Malard F; Harousseau JL; Mohty M
    Blood Cancer J; 2021 May; 11(5):97. PubMed ID: 34006856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. AL amyloidosis: untangling new therapies.
    Bal S; Landau H
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):682-688. PubMed ID: 34889374
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Updates in the Diagnosis and Management of AL Amyloidosis.
    Cook J; Muchtar E; Warsame R
    Curr Hematol Malig Rep; 2020 Jun; 15(3):155-167. PubMed ID: 32394186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.
    Hari P; Lin HM; Asche CV; Ren J; Yong C; Luptakova K; Faller DV; Sanchorawala V
    Amyloid; 2018 Mar; 25(1):1-7. PubMed ID: 29303358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How I Approach Light Chain Amyloidosis.
    Chowdhury RB; Leung N
    G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation.
    Havasi A; Doros G; Sanchorawala V
    Am J Hematol; 2018 May; 93(5):E129-E132. PubMed ID: 29430701
    [No Abstract]   [Full Text] [Related]  

  • 49. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type.
    Muchtar E; Dispenzieri A; Kumar SK; Buadi FK; Lacy MQ; Zeldenrust S; Hayman SR; Leung N; Chakraborty R; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Go R; Kyle RA; Rajkumar VS; Gertz MA
    Amyloid; 2017 Mar; 24(sup1):44-45. PubMed ID: 28434304
    [No Abstract]   [Full Text] [Related]  

  • 50. How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis).
    Chaulagain CP; Herlitz LC; Fu J; Bilani N; Lucitt C; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e826-e831. PubMed ID: 32703752
    [No Abstract]   [Full Text] [Related]  

  • 51. Amyloidosis of the Heart and Kidney.
    Adrogue HE
    Methodist Debakey Cardiovasc J; 2022; 18(4):27-33. PubMed ID: 36132587
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis.
    Merlini G; Sarosiek S; Benevolo G; Cao X; Dimopoulos M; Garcia-Sanz R; Gatt ME; Fernandez de Larrea C; San-Miguel J; Treon SP; Minnema MC
    Semin Hematol; 2023 Mar; 60(2):113-117. PubMed ID: 37099030
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Once AL amyloidosis: not always AL amyloidosis.
    Jhaveri T; Sarosiek S; Ruberg FL; Siddiqi O; Berk JL; Sanchorawala V
    Amyloid; 2018 Jun; 25(2):139-140. PubMed ID: 29516761
    [No Abstract]   [Full Text] [Related]  

  • 54. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ptosis and macroglossia in a woman with systemic light-chain amyloidosis.
    Hsiao PJ; Chang YC; Tsao YH; Wu KL; Kao YH; Chan JS; Wang CH; Lin YY; Chuu CP; Lin YS
    Clin Chim Acta; 2019 Jul; 494():112-115. PubMed ID: 30905590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Blood; 2020 Dec; 136(23):2620-2627. PubMed ID: 33270858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.
    Gertz MA; Dispenzieri A
    JAMA; 2020 Jul; 324(1):79-89. PubMed ID: 32633805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Primary amyloidosis].
    González de la Calle V; García-Sanz R; Mateos MV
    Med Clin (Barc); 2016 Aug; 147(3):121-6. PubMed ID: 27085744
    [No Abstract]   [Full Text] [Related]  

  • 59. [Light chain amyloidosis].
    Hegenbart U; Aus dem Siepen F; Schönland S
    Inn Med (Heidelb); 2023 Sep; 64(9):842-847. PubMed ID: 37540260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.